


I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV419116871US, in an envelope addressed to: MS Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 12/21/04

Signature: Judy Bridgwater

(Judy Bridgwater)

Docket No.: 549172000100
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Micheal L. GRUENBERG

Application No.: 08/700,565

Filed: July 25, 1996

For: AUTOLOGOUS IMMUNE CELL THERAPY:
CELL COMPOSITIONS, METHODS AND
APPLICATIONS TO TREATMENT OF
HUMAN DISEASE

Art Unit: 1644

Examiner: R. Schwadron

PETITION TO WITHDRAW HOLDING OF ABANDONMENT

MS Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


This is in response to the Notice of Abandonment dated December 2, 2004. The Notice states that the application has been abandoned for failure to timely respond to the Office communication mailed May 26, 2004. Enclosed herewith are copies of the Amendment in Response to Office Communication which was mailed November 24, 2004 via Express Mail. Also enclosed is a copy of the date-stamped Express Mail Label, and a copy of the return postcard stamped received by the USPTO on November 24, 2004. Applicants hereby request withdrawal of the holding of abandonment and entry of the response then filed.

In the event the U.S. Patent and Trademark office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. **549172000100**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: December 21, 2004

Respectfully submitted,

By


Laurie L. Hill, Ph.D.

Registration No.: 51,804

MORRISON & FOERSTER LLP

3811 Valley Centre Drive, Suite 500

San Diego, California 92130

(858) 720-7955

COPY

Customer Cc
Label 11-F June



EV 419116956 US



UNITED STATES POSTAL SERVICE®

Post Office To Address

ORIGIN (POSTAL USE ONLY)		
PO ZIP Code 92110	Day of Delivery <input type="checkbox"/> Next <input checked="" type="checkbox"/> Second	Flat Rate Envelope <input type="checkbox"/>
Date In 11/24/04	<input checked="" type="checkbox"/> 12 Noon <input type="checkbox"/> 3 PM	Postage \$ 13.65
Time In 6:54	Military <input type="checkbox"/> 2nd Day <input type="checkbox"/> 3rd Day	Return Receipt Fee
Weight 3.3 lbs. ozs.	Int'l Alpha Country Code	COD Fee Insurance Fee
No Delivery <input type="checkbox"/> Weekend <input type="checkbox"/> Holiday	Acceptance Clerk Initials [Signature]	Total Postage & Fees \$ 13.65

DELIVERY (POSTAL USE ONLY)		
Delivery Attempt	Time	Employee Signature
Mo. Day	<input type="checkbox"/> AM <input type="checkbox"/> PM	
Delivery Attempt	Time	Employee Signature
Mo. Day	<input type="checkbox"/> AM <input type="checkbox"/> PM	
Delivery Date	Time	Employee Signature
Mo. Day	<input type="checkbox"/> AM <input type="checkbox"/> PM	
<input type="checkbox"/> WAIVER OF SIGNATURE (Domestic Only) Additional merchandise insurance is void if waiver of signature is requested. I wish delivery to be made without obtaining signature of addressee or addressee's agent (if delivery employee judges that article can be left in secure location) and I authorize that delivery employee's signature constitutes valid proof of delivery.		
NO DELIVERY <input type="checkbox"/> Weekend <input type="checkbox"/> Holiday		

CUSTOMER USE ONLY
METHOD OF PAYMENT:
Express Mail Corporate Acct. No. **692100**

Federal Agency Acct. No. or
Postal Service Acct. No.

FROM: (PLEASE PRINT)
PHONE **(658) 720 5100**

MORRISON & FOERSTER LLP
3011 VALLEY CENTRE DR STE 500
SAN DIEGO CA 92106-5313

54917-10001.00 8894/LLH12

TO: (PLEASE PRINT)

MAIL STOP
COMMISSIONER FOR PATENTS
PO BOX 1450
ALEXANDRIA VA 22313-1450

[Circular Postmark: SAN DIEGO CA 92106 NOV 24 2004]

PRESS HARD.

You are making 3 copies.

FOR PICKUP OR TRACKING CALL 1-800-222-1811 www.usps.com



Atty Docket No.: 549172000100

Inventor: Micheal L. GRUENBERG

Application No.: 08/700,565

Filing Date: July 25, 1996

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS,
METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Documents Filed:

Transmittal (1 page)

Fee Transmittal (1 page, + duplicate)

Petition for Extension of Time Under 37 CFR 1.136(a) (1 page)

Amendment in Response to Office Communication (2 pages)

NXM

RECEIVED
DEC 03 2004
Morrison & Foerster, LLP
RECEIVED



Via: Express Mail: Airbill No. EV 419116956 US

Sender's Initials: LLH12/jab15

[Handwritten: me]

Date: November 24, 2004


 COPY

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after )	Application Number	08/700,565	
	Filing Date	July 25, 1996	
	First Named Inventor	Micheal L. GRUENBERG	
	Art Unit	1644	
	Examiner Name	R. Schwadron	
Total Number of Pages in This Submission	10	Attorney Docket Number	549172000100

ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form (1 pg., + dup.) <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply (6 pgs.) <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input checked="" type="checkbox"/> Extension of Time Request (1 pg.) <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Receipt Postcard
Remarks Customer No. 25225		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	MORRISON & FOERSTER LLP		
Signature			
Printed name	Laurie L. Hill		
Date	November 24, 2004	Reg. No.	51,804

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 419116956 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below

Dated: November 24, 2004

Signature:  (Judy Bridgwater)

sd-232555

 **COPY**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 419116956 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 11/24/04

Signature: Judy Bridgewater
(Judy Bridgewater)

Docket No.: 549172000100
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Micheal L. GRUENBERG

Application No.: 08/700,565

Filed: July 25, 1996

For: AUTOLOGOUS IMMUNE CELL THERAPY:
CELL COMPOSITIONS, METHODS AND
APPLICATIONS TO TREATMENT OF
HUMAN DISEASE



Examiner: R. Schwadron

Art Unit: 1644

AMENDMENT IN RESPONSE TO OFFICE COMMUNICATION

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This is in response to the Office Communication dated May 26, 2004, for which a response was due on June 26, 2004. Filed herewith is a Petition and fee for a five-month extension of time, thereby extending the deadline for response to November 26, 2004. Accordingly, this response is timely filed. Reconsideration and allowance of the pending claims, as amended, are respectfully requested.

AMENDMENTS TO THE CLAIMS

Claims 1-21 (Canceled)

Claim 22 (Currently amended): A method for generating clinically relevant cell numbers of Th1 cells, comprising:

(a) collecting material containing mononuclear T lymphoid cells from a mammal;
(b) activating the T lymphoid cells to alter their cytokine production profile by causing differentiation of the cells into Th1 cell, wherein the cells are activated in the presence of either or both interferon- γ and IL-2 or anti-IL-4 antibody or α B7.2 mAb or TGF- β , whereby cells differentiate into Th1 cells; and

(c) in the absence of exogenous IL-2 H-2, inducing cell proliferation and expanding the cells under conditions that produce at least about 10^{10} cells/liter of a homogeneous population of Th1 cells, wherein:

a homogeneous population of Th1 cells comprises greater than about 50% Th1 cells; and

the resulting cells do not require co-infusion of IL-2 for activity.

Claim 23 (Previously presented): The method of claim 22, wherein the Th1 cells with altered cytokine profile are purified.

Claim 24 (Previously Presented): The method of claim 22, wherein the Th1 cells with altered cytokine profile are specific for a defined antigen.

Claim 25 (Previously Presented): The method of claim 23, wherein the Th1 cells with altered cytokine profile are specific for a defined antigen.

Claims 26-28 (Canceled)

Claim 29 (Currently amended): The method of claim ~~[[28 22]]~~, wherein anti-IL-4 monoclonal antibodies are also present during activation.

Claim 30 (Canceled)

Claim 31 (Previously Presented): The method of claim 22, wherein the cells are expanded in the presence of two or more monoclonal antibodies.

Claim 32 (Previously Presented): The method of claim 31, wherein the monoclonal antibodies are specific for CD3 or CD2, combined with any combination of monoclonal antibodies specific for one or more of the following: CD4, CD8, CD11a, CD27, CD28, CD44 and CD45RO.

Claim 33 (Original): The method of claim 22, wherein the cells are expanded in a hollow fiber bioreactor.

Claims 34-154 (Canceled)

Claim 155 (Currently amended): A method for generating clinically relevant numbers of Th1 cells for autologous cell therapy, comprising:

(a) collecting material comprising body fluid or tissue containing mononuclear cells from a mammal;

(b) treating the cells to induce differentiation of mononuclear cells into Th1 cells, wherein the cells are treated with either or both interferon- γ and IL-2, or anti-IL-4 antibody or α B7.2 mAb or TGF- β to induce differentiation of Th1 cells; and

(c) contacting the resulting differentiated cells with two or more different activating proteins specific for cell surface proteins present on the cells in an amount sufficient to induce *ex vivo* cell expansion, whereby clinically relevant numbers of cells for autologous cell therapy are generated, wherein the contacting is effected in the absence of exogenous cytokines [[IL-2]].

Claim 156 (Previously Presented): The method of claim 155, wherein cells are purified from the material.

Claim 157 (Currently amended): The method of claim 155, wherein the treating and ~~contacting steps~~ step occurs in the absence of exogenous cytokines.

Claim 158 (Previously Presented): The method of claim 155, wherein the cells are specific for a selected antigen.

Claims 159-164 (Canceled)

Claim 165 (Previously Presented): The method of claim 155, wherein the proteins specific for cell surface proteins are one or more monoclonal antibodies specific for immune cell surface proteins.

Claim 166 (Previously Presented): The method of claim 165, wherein the monoclonal antibodies are specific for CD3 or CD2, combined with any combination of monoclonal antibodies specific for one or more antigens selected from the group consisting of CD4, CD8, CD11a, CD27, CD28, CD44 and CD45RO.

Claim 167 (Previously Presented): The method of claim 155, wherein cell expansion is effected in a hollow fiber bioreactor.

Claim 168 (Previously Presented): The method of claim 155, wherein the cells are expanded to about 10^9 cells or greater.

Claim 169 (Canceled)

Claim 170 (Currently amended): The method of claim 155, wherein the expanded cells are predominantly Th1, ~~Th2~~, ~~Th3~~ cells.

Claim 171 (Previously Presented): The method of claims 155, wherein the expanded cells are contained in a volume of one liter or less.

Claim 172 (Previously Presented): The method of claim 155, wherein the expanded cells are contained in a volume of about 500 mls or less.

Claims 173-210 (Canceled)

Claim 211 (Currently amended): A method for generating immune cells for autologous cellular immunotherapy, comprising:
collecting leukocyte containing material from a mammal;

differentiating the leukocytes into Th1 cells by contacting the cells with a composition comprising interferon- γ , or anti-IL-4 antibody or α B7.2 mAb or TGF- β ; and

exposing the leukocyte-containing material to two or more different mitogenic monoclonal antibodies to induce *in vitro* cell proliferation of Th1 cells sufficient for infusion into the mammal for use in an immunotherapy treatment, wherein the *in vitro* cell proliferation is produced without the use of exogenous interleukin-2.

Claim 212 (Previously Presented): The method of claim 211, wherein at least 10^{10} cells are produced.

Claim 213 (Previously Presented): The method of claim 211, wherein the cells are at a density of 1×10^8 cells/ml.

Claims 214-217 (Canceled)

REMARKS

Claims 22-25, 29, 31-33, 155-158, 165-168, 170-172 and 211-213 are pending in this application. Claims 22, 29, 155, 157, 170, and 211 are amended herewith. It is believe that no new matter is added. No claim has been allowed.


According to the Office Communication dated May 26, 2004, the amendment to the claims filed on January 30, 2003 does not comply with the requirements of 37 C.F.R. § 121(c) because the terms "by contacting the cells with" and "two or more" were added to the claim 211 without indicating that the phrases were added. Applicants submit a complete set of amended claims as they appeared in the amendment filed January 30, 2003 with the indicated phrases underlined to comply with the *current* requirement of 37 C.F.R. § 121(c). Applicants also note that minor errors in the claims as filed on January 30, 2003 are also corrected by the amendments submitted herewith.

Applicants respectfully request the substantive consideration of the claims as now pending.

In the event the U.S. Patent and Trademark office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 54917-20001.00. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: November 24, 2004

Respectfully submitted,

By 
Laurie L. Hill, Ph.D.
Registration No.: 51,804
MORRISON & FOERSTER LLP
3811 Valley Centre Drive, Suite 500
San Diego, California 92130
(858) 720-7955

12-23-04

ifw



PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	08/700,565
	Filing Date	July 25, 1996
	First Named Inventor	Micheal L. GRUENBERG
	Art Unit	1644
	Examiner Name	R. Schwadron
	Attorney Docket Number	549172000100
Total Number of Pages in This Submission		11

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input checked="" type="checkbox"/> Petition (2 pages) <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1) Copy of Response to Office Communication mailed November 24, 2004 (7 Pages) 2) Copy of date-stamped Express Mail Label and copy of dated-stamped return postcard (1 page) 4) Return receipt postcard
<div>Remarks</div> <p>Customer No. 25225</p>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	MORRISON & FOERSTER LLP Laurie L. Hill, Ph.D. - 51,804
Signature	
Date	December 21, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 419116871 US, in an envelope addressed to: MS Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: 12/21/04	Signature: (Judy Bridgwater)